University Hospital Regensburg

Axatilimab Approved for Chronic GVHD After Failure of Two Prior Therapies

- Axatilimab has received FDA approval for treating chronic graft-versus-host disease (GVHD) in patients who have not responded to at least two prior systemic therapies. - Chronic GVHD can affect almost any organ in the body, leading to significant symptom burden and long-term immunosuppression requirements for affected individuals. - Current GVHD prevention methods, such as calcineurin inhibitors and methotrexate, have reduced incidence rates, but effective treatments are still needed for those affected. - Emerging strategies like graft engineering with platforms such as Orca-T show promise in further reducing chronic GVHD rates, but the disease is unlikely to vanish completely.